Status:
UNKNOWN
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Lead Sponsor:
Cellect Biotechnology
Conditions:
Acute Myelogenous Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Eligibility:
All Genders
18-70 years
Brief Summary
This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects who completed study ApoGraft-01 through 180 days (6 months) post-transplantation
- Ability to comply with the requirements of the study.
- Signed written informed consent
Exclusion
Key Trial Info
Start Date :
June 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03260101
Start Date
June 10 2018
End Date
December 1 2021
Last Update
November 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Medical Center
Haifa, Israel